Sunosi (solriamfetol) + Other prescription wake-promoting medications or stimulants
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Narcolepsy
Conditions
Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
Trial Timeline
Jul 31, 2019 → Sep 1, 2029
NCT ID
NCT06413420About Sunosi (solriamfetol) + Other prescription wake-promoting medications or stimulants
Sunosi (solriamfetol) + Other prescription wake-promoting medications or stimulants is a pre-clinical stage product being developed by Axsome Therapeutics for Narcolepsy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06413420. Target conditions include Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06413420 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Narcolepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2086 + E2086 Placebo + Active Comparator + Active Comparator Placebo | Eisai | Phase 1 | 33 |
| MK-6552 + Placebo | Merck | Phase 1 | 33 |
| Sodium Oxybate (Xyrem) | UCB | Phase 1 | 30 |
| JZP-110 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| ADX-N05 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| Xyrem | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP258 | Jazz Pharmaceuticals | Approved | 82 |
| ADX-N05 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| Xyrem (sodium oxybate) oral solution | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP-258 | Jazz Pharmaceuticals | Approved | 82 |
| JZP441 + Matching Placebo | Jazz Pharmaceuticals | Phase 1 | 30 |
| Xyrem + Xyrem Placebo + Modafinil at established dose + Modafinil (Placebo) | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP-110 + Placebo oral tablet | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP-258 | Jazz Pharmaceuticals | Phase 3 | 74 |
| Transition from Xyrem to Xywav | Jazz Pharmaceuticals | Pre-clinical | 20 |
| JZP-110 | Jazz Pharmaceuticals | Phase 3 | 74 |
| AXS-12 (reboxetine) + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg Oral Tablet | Axsome Therapeutics | Phase 1 | 30 |
| AXS-12 (Reboxetine) + Placebo | Axsome Therapeutics | Phase 2 | 49 |
| AXS-12 (reboxetine) + Placebo | Axsome Therapeutics | Phase 3 | 74 |